Loading stock data…
DNLI
$18.30-0.42 (-2.24%)
Market ClosedLast close May 1
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Denali Therapeutics Inc. in the Healthcare sector is trading at $18.30. The stock is currently 23% below its 52-week high of $23.77, remaining 4.9% above its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why DNLI maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$18.30
Potential Upside
5%
Whystock Fair Value$19.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$35.64+94.8%
Range$25.00 – $42.00
Fundamentals
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflamma...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.21B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.25%
Volume
Today's trading volume
1.50M
Recent News
What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in
Denali Therapeutics Inc. (NASDAQ:DNLI) is one of the 10 best biotech stocks with highest upside potential. On April 6, Denali Therapeutics Inc. (NASDAQ:DNLI) revealed that it has received notice from Takeda (NYSE: TAK) about the termination of the collaboration agreement on developing and commercializing DNL593. This move was due to some strategic reasons and is […]
Bernstein Upgrades Takeda Pharmaceutical (TAK) to Outperform
Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the 10 Stocks to Buy on a Pullback. On April 8, 2026, Bernstein upgraded Takeda Pharmaceutical Company Limited (NYSE:TAK) to Outperform from Market Perform and raised its price target to ¥6,900 from ¥5,100, citing “bold” cost-cutting measures and a series of upcoming pipeline catalysts that could help […]
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
DNLI secures FDA nod for Avlayah, a first-in-decades Hunter syndrome therapy, but pipeline risks and Takedas exit complicate the outlook.
A Look At Takeda Pharmaceutical (TSE:4502) Valuation After Mixed Pipeline News On DNL593 And Zasocitinib
Takeda Pharmaceutical (TSE:4502) is back in focus after two contrasting pipeline updates: a terminated collaboration with Denali Therapeutics on DNL593 for frontotemporal dementia and positive Phase 3 data for psoriasis candidate zasocitinib. See our latest analysis for Takeda Pharmaceutical. The recent mix of positive zasocitinib Phase 3 data and the DNL593 collaboration exit has come against a backdrop of strong momentum, with a 30 day share price return of 3.06% and a 1 year total...
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
DNLI's shares decline after Takeda exits DNL593 partnership, leaving Denali to fully control and fund the therapy as it advances studies and plans 2026 data release.